Lumira Capital

About Lumira Capital

Lumira Capital leverages over 25 years of experience as one of North America's leading health care and life sciences venture capital investors. The firm invests in biopharmaceutical, medical device, health IT and consumer health companies whose products deliver transformative improvements in the lives of patients worldwide. Lumira Capital's investment team has extensive industry experience as entrepreneurs, researchers, clinicians, business development professionals and investors. In addition to a longstanding presence in the U.S. with offices in Boston and San Diego, the firm continues to be the most active domestic health care investor in Canada, where it has offices in Toronto, Montreal and Vancouver.\\Over the past five years Lumira Capital's partners have helped build more than 50 companies. Recent successes include the acquisitions of portfolio companies such as Morphotek, (by Eisai Co.), Alveolus (by Asset purchase by Merit Medical), Guava (by Millipore), Corus Pharma (by Gilead Sciences), as well as the IPOs of Alexza Pharmaceuticals, Replidyne, Pharmasset and MAKO Surgical. Other portfolio companies and recent investments include Argos Therapeutics, Archemix, Ception Therapeutics, Cardiac Dimensions and Spinal Kinetics. Lumira Capital invests primarily in North American emerging-stage biopharmaceutical and medical device companies and has offices in Canada (Toronto, Montreal) and the U.S. (San Francisco and Boston)